Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alliancaude e ParticipacoesBSP:AALR3 +0.61%36 EV-to-OCF is 5.80 as of Sep. 05, 2026, which is 64% below its 10-year median of 16.19. GuruFocus rates BSP:AALR3 with a GF Score™ of 36/100 and a GF Value™ of R$7.31 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Alliancaude e Participacoes ranks better than 50.7% on this metric.
The historical rank and industry rank for Alliancaude e Participacoes's EV-to-OCF or its related term are showing as below:
BSP:AALR3'
s EV-to-OCF Range Over the Past 10 Years
Min: -59.63 Med: 16.19 Max: 288.46
Current: 5.68
During the past 12 years, the highest EV-to-OCF of Alliancaude e Participacoes was 288.46. The lowest was -59.63. And the median was 16.19.
BSP:AALR3's EV-to-OCF is ranked better than 50.7% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 5.92
vs BSP:AALR3: 5.68
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alliancaude e Participacoes (BSP:AALR3) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alliancaude e Participacoes's PE Ratio (TTM) for today is calculated as:
Alliancaude e Participacoes's share price for today is R$3.30.
Alliancaude e Participacoes's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-8.992.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Alliancaude e Participacoes EV-to-OCF Related Terms
Alliancaude e Participacoes EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Alliancaude e Participacoes's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alliancaude e Participacoes EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Alliancaude e Participacoes's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Alliancaude e Participacoes's EV-to-OCF falls into.
Alliancaude e Participacoes's current Enterprise Value is R$1,164 Mil.
Alliancaude e Participacoes's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was R$201 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alliancaude e Participacoes (BSP:AALR3) has a EV-to-OCF of 5.80 as of Sep. 05, 2026. This is 64% below median its historical median of 16.19. According to the industry distribution chart, Alliancaude e Participacoes ranks #105 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 49.3%.
Is Alliancaude e Participacoes' EV-to-OCF too high?
Alliancaude e Participacoes' current EV-to-OCF of 5.80 is 64% below median its 10-year median of 16.19. The Medical Diagnostics & Research industry median EV-to-OCF is 5.92. Alliancaude e Participacoes' value of 5.80 is 2% below this industry median. Based on the distribution chart, Alliancaude e Participacoes ranks #105 out of 213 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Alliancaude e Participacoes has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alliancaude e Participacoes' EV-to-OCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Alliancaude e Participacoes ranks #105 out of 213 companies for EV-to-OCF. This puts Alliancaude e Participacoes in the upper half of its industry. The industry median EV-to-OCF is 5.92. Alliancaude e Participacoes' value of 5.80 is 2% below this benchmark. While the company's 10-year median is 16.19 vs. the industry median of 5.92, Alliancaude e Participacoes has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 5.92, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alliancaude e Participacoes's current EV-to-OCF of 5.80 is 2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 5.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alliancaude e Participacoes's current EV-to-OCF is 5.80, which is 64% below median its own 10-year median of 16.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alliancaude e Participacoes stock overvalued right now?
Based on GuruFocus' analysis, Alliancaude e Participacoes (BSP:AALR3) is currently considered Possible Value Trap. The stock's GF Value™ is R$7.31, compared to a current price of R$3.30 — trading 54.9% below its estimated fair value. The current EV-to-OCF is 5.80, which is 64% below median its 10-year median of 16.19 and 2% below the Medical Diagnostics & Research industry median of 5.92. Alliancaude e Participacoes' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Alliancaude e Participacoes (BSP:AALR3), the current EV-to-OCF is 5.80 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alliancaude e Participacoes (BSP:AALR3) Overvalued in 2026?
Based on GuruFocus' analysis, Alliancaude e Participacoes stock appears to be undervalued.
The current stock price of R$3.30 is trading 54.9% below its estimated GF Value™ of R$7.31.
GuruFocus considers Alliancaude e Participacoes to be Possible Value Trap.
Key valuation signals for BSP:AALR3:
EV-to-OCF: 5.80 (64% below median its 10-year median of 16.19)
GF Value™: R$7.31 vs. price of R$3.30 (54.9% below fair value)
Industry Position: 2% below the Medical Diagnostics & Research median (#105 of 213)
No single metric tells the full story. See the BSP:AALR3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Allianca Saude e Participacoes SA formerly Centro de Imagem Diagnosticos SA - Alliar is a diagnostic imaging company consisting of MRI machines, CT scanners and ultrasound machines. Its products include diagnostic medicine, diagnostic imaging and clinical analysis. The company is also engaged in the import of medical and hospital equipment, diagnosis kits, and related goods; Providing health consulting, advisory, courses and lectures.
36GF Score
Get the complete analysis for BSP:AALR3
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:AALR3 has been successfully added to your 
